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PLipids and Coronary Disease
Beyond Low-Density Lipoprotein Cholesterol
Respective Contributions of Non–High-Density
Lipoprotein Cholesterol Levels, Triglycerides, and the
Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio to
Coronary Heart Disease Risk in Apparently Healthy Men and Women
Benoit J. Arsenault, PHD,*† Jamal S. Rana, MD, PHD,§ Erik S. G. Stroes, MD, PHD,
Jean-Pierre Després, PHD,*‡ Prediman K. Shah, MD,§ John J. P. Kastelein, MD, PHD,
Nicholas J. Wareham, MBBS, PHD,# S. Matthijs Boekholdt, MD, PHD,¶ Kay-Tee Khaw, MBBCHIR**
Québec, Québec, Canada; Los Angeles, California; Amsterdam, the Netherlands; and Cambridge, United Kingdom
Objectives This study was designed to test the hypothesis that at any low-density lipoprotein cholesterol (LDL-C) level, other lipid
parameters such as non–high-density lipoprotein cholesterol (HDL-C) levels, triglyceride (TG) levels, and the total cho-
lesterol (TC)/HDL-C are still associated with an increased coronary heart disease (CHD) risk.
Background Although LDL-C is considered to be the primary target of lipid-lowering therapy, other parameters of the
lipoprotein-lipid profile may more closely associated with CHD risk.
Methods In the EPIC (European Prospective Investigation Into Cancer and Nutrition)-Norfolk prospective population study,
21,448 participants without diabetes or CHD between age 45 and 79 years were followed for 11.0 years. A total
of 2,086 participants developed CHD during follow-up.
Results Among individuals with low LDL-C levels (100 mg/dl), after adjustment for age, sex, smoking, systolic blood
pressure, waist circumference, physical activity, and hormone replacement therapy (in women), those with non–
HDL-C 130 mg/dl had a hazard ratio (HR) for future CHD of 1.84 (95% confidence interval [CI]: 1.12 to 3.04)
when compared with those with non–HDL-C levels 130 mg/dl. In a similar model, individuals with TG levels
150 mg/dl had an HR of 1.63 (95% CI: 1.02 to 2.59) when compared with those with TG levels 150 mg/dl,
and individuals with a TC/HDL-C ratio 5 had an HR of 2.19 (95% CI: 1.22 to 3.93) when compared with those
with a TC/HDL-C ratio 5.
Conclusions In this prospective study, independently of their plasma LDL-C levels, participants with high non–HDL-C levels,
high TG levels, or with an elevated TC/HDL-C ratio were at increased CHD risk. CHD risk assessment algorithms
as well as lipid targets of lipid-lowering trials may also need to consider other easily available parameters such
as non–HDL-C. (J Am Coll Cardiol 2010;55:35–41) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.057v
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aver the past decades, numerous population-based and
ntervention studies have identified low-density lipoprotein
holesterol (LDL-C) as a key risk factor for coronary heart
isease (CHD) (1–5). Based on this evidence, guidelines of
he National Cholesterol Education Program-Adult Treat-
ent Panel III suggest that first-line therapy should be
irected toward LDL-C lowering (6,7). However, although
any trials have documented the benefits of lowering
lasma LDL-C levels for the primary and secondary pre-
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etherlands; and the #Medical Research Council Epidemiology Unit and **De- aention of CHD, studies have shown that individuals
eaching their LDL-C target may still be at increased CHD
isk if they have detrimental levels of other parameters of the
See page 42
ipoprotein-lipid profile (8). In this regard, it has recently
een proposed that other lipid parameters such as choles-
erol levels in lipoproteins other than high-density lipopro-
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rants from the Medical Research Council U.K. and Cancer Research U.K. and with
dditional support from the European Union, Stroke Association, British Heart Foundation,
nd Research into Ageing. Drs. Arsenault and Rana contributed equally to this work.Manuscript received April 17, 2009; revised manuscript received June 16, 2009,
ccepted July 12, 2009.
d
n
r
a
t
i
o
r
M
S
g
p
4
K
s
r
N
d
c
s
d
K
t
i
i
b
1
q
a
a
s
l
s
U
t
b
u
N
e
b
s
c
a
c
a
c
(
i
b
A
c
d
f
C
m
m
1
i
i
b
e
A
p
s
w
y
S
p
f
S
h
i
c
1
N
P
m
n
f
1
a
t
d
a
a
T
c
n
f
a
36 Arsenault et al. JACC Vol. 55, No. 1, 2010
Lipids and CHD Risk December 29, 2009/January 5, 2010:35–41teins (HDLs) (i.e., non–high-
density lipoprotein cholesterol
[HDL-C] levels), triglyceride
(TG) levels, or the total choles-
terol (TC) to HDL-C ratio
could better predict cardiovascu-
lar outcomes in patients on
LDL-C–lowering therapy (8,9).
However, there is a lack of epi-
demiological data to suggest that
the aforementioned parameters
of the lipoprotein-lipid profile
could better predict CHD risk
than LDL-C in asymptomatic
individuals.
The objective of the present
study was to investigate the rela-
tive contributions of several in-
exes of the lipid-lipoprotein profile, namely LDL-C,
on–HDL-C, and TG levels as well as the TC to HDL-C
atio, to the risk of CHD in a study cohort representative of
contemporary Western population. In addition, we tested
he hypothesis that independently from LDL-C levels,
ndividuals with high non–HDL-C levels, high TG levels,
r with a high TC to HDL-C ratio still have an increased
isk of developing CHD.
ethods
tudy design. The EPIC (European Prospective Investi-
ation Into Cancer and Nutrition)-Norfolk study is a
opulation-based study of 25,668 men and women between
5 and 79 years of age who are residents of Norfolk, United
ingdom, and who completed a baseline questionnaire
urvey and attended a clinic visit (10). Participants were
ecruited from age-sex registers of general practices in
orfolk as part of the 10-country collaborative EPIC study
esigned to investigate dietary and other determinants of
ancer. Additional data were obtained in the EPIC-Norfolk
tudy to enable the assessment of determinants of other
iseases. The study cohort was closely similar to United
ingdom population samples with regard to many charac-
eristics, including anthropometry, blood pressure, and lip-
ds, but with a lower proportion of smokers.
The design and methods of the study have been described
n detail (10). In short, eligible participants were recruited
y mail. At the baseline survey conducted between 1993 and
997, participants completed a detailed health and lifestyle
uestionnaire. Blood was taken by venipuncture into plain
nd citrate tubes. Blood samples were processed for various
ssays at the Department of Clinical Biochemistry, Univer-
ity of Cambridge, or stored at –80°C. Nonfasting serum
evels of TC, HDL-C, and TG were measured on fresh
amples with the RA 1000 (Bayer Diagnostics, Basingstoke,
nited Kingdom), and LDL-C levels were calculated with
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
TC  total cholesterol
TG  triglyceridehe Friedewald formula (11). Non–HDL-C was calculated cy subtracting HDL-C levels from TC levels. All individ-
als were flagged for mortality at the U.K. Office of
ational Statistics, with vital status ascertained for the
ntire cohort. Death certificates for all decedents were coded
y trained nosologists according to the International Clas-
ification of Diseases (ICD)-Ninth Revision. Death was
onsidered due to CHD if the underlying cause was coded
s ICD 410 to ICD 414. These ICD codes encompass the
linical spectrum of CHD—unstable angina, stable angina,
nd myocardial infarction. Previous validation studies in our
ohort indicated high specificity for such case ascertainment
12). In addition, participants admitted to hospital were
dentified by their unique National Health Service number
y data linkage with the ENCORE (East Norfolk Health
uthority database) registry, which identifies all hospital
ontacts throughout England and Wales for Norfolk resi-
ents. Participants were identified as having CHD during
ollow-up if they had a hospital admission and/or died with
HD as an underlying cause. Individuals with diabetes
ellitus were excluded from the present analyses. Diabetes
ellitus status was ascertained by means of the following:
) self-report of diabetes medication use; 2) diabetes med-
cation brought to the baseline health check; 3) the partic-
pant indicating modification of the diet in the past year
ecause of diabetes; or 4) the participant indicating adher-
nce to a diabetic diet. The Norwich District Health
uthority Ethics Committee approved the study, and all
articipants gave signed informed consent. We report re-
ults of 21,448 individuals without CHD at baseline who
ere followed up to March 2007, an average of 11.0  2.0
ears.
tatistical analyses. Baseline characteristics were com-
ared between participants who developed CHD during
ollow-up versus those who did not using an unpaired
tudent t test. Cox regression analysis was used to calculate
azard ratios (HRs) and corresponding 95% confidence
ntervals (CIs) for the risk of future CHD in pre-specified
ategories of LDL-C (100 mg/dl, 100 to 129.9 mg/dl,
30 to 159.9 mg/dl, and 160 mg/dl as suggested by the
ational Cholesterol Education Program-Adult Treatment
anel III [7]), non–HDL-C (130 mg/dl, 130 to 159.9
g/dl, 160 to 189.9 mg/dl, and190 mg/dl [thresholds for
on–HDL-C are parallel to those for LDL-C but the
ormer are 30 mg/dl higher]), and TG levels (150 mg/dl,
50 to 199.9 mg/dl, 200 to 249.9 mg/dl, and 250 mg/dl),
nd of the TC to HDL-C ratio (4.00, 4.00 to 4.99, 5.00
o 5.99, and 6.00). Because TG levels had a skewed
istribution, values were log-transformed before being used
s a continuous variable in this model. Hazard ratios were
lso calculated per 1-SD increase of LDL-C, non–HDL-C,
G levels, and TC to HDL-C ratio. The SD units
orresponded to 40.2 mg/dl for LDL-C, 45.2 mg/dl for
on–HDL-C, 74.3 mg/dl for log-transformed TG and 1.56
or the TC to HDL-C ratio. Cox regression analysis was
lso used to calculate HR for future CHD in individuals
lassified on the basis of LDL-C levels (100 mg/dl, 100 to
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December 29, 2009/January 5, 2010:35–41 Lipids and CHD Risk29.9 mg/dl, 130 to 159.9 mg/dl, and 160 mg/dl) with
igh non–HDL-C (maximal LDL-C level plus 30 mg/dl),
G (150 mg/dl), and TC to LDL-C ratio (5.00). All
Rs were adjusted for age, sex (when sexes were combined),
moking, waist circumference, physical activity, systolic
lood pressure (when sexes were combined), and hormone
eplacement therapy use (for women only). Kaplan-Meier
urvival curves were computed for participants classified into
groups—above or below the median for: 1) LDL-C and
on–HDL-C levels; 2) LDL-C and TG levels; and 3)
DL-C levels and the TC to HDL-C ratio. Differences
etween curves were assessed by log-rank test. Statistical
nalyses were performed using SPSS software (version
2.0.1, SPSS Inc., Chicago, Illinois). A p value 0.05 was
onsidered statistically significant.
esults
mong the 9,348 male study participants, 1,310 developed
HD during follow-up of 11.0 years, and among the
2,100 women, 776 developed CHD during follow-up.
aseline characteristics of participants who developed CHD
ersus those who did not are shown in Table 1 for men and
omen separately. In both sexes, participants who devel-
ped CHD were older and had higher blood pressure and a
ore detrimental lipid profile than those who remained free
rom CHD during follow-up.
Table 2 presents the adjusted HRs for future CHD
ccording to LDL-C levels, non–HDL-C levels, TG levels,
aseline Characteristics of Men and Women Included in EPIC-Norfoev oped CHD During the Study Follow-Up Versus Participants WhTable 1 B seline Charac ristics of M and Women IncludedDeveloped CHD During the Study Follow-Up Versus Par
Men
Without CHD
Number of participants 8,038
Age, yrs 58 9
Smoking
Current 11.6 (934) 1
Past 52.1 (4,189) 5
Never 36.3 (2,915) 2
Hormone replacement therapy N/A
Physical activity
Active 23.9 (1,924) 1
Moderately active 24.0 (1,932) 2
Moderately inactive 25.0 (2,010) 2
Inactive 27.0 (2,172) 3
Waist circumference, cm 95 9
Systolic blood pressure, mm Hg 136 17
Diastolic blood pressure, mm Hg 84 11
TC, mg/dl 230.1 40.9
LDL-C, mg/dl 149.8 37.1
HDL-C, mg/dl 48.3 13.1
Non–HDL-C, mg/dl 181.9 41.7
TC/HDL-C 5.07 1.54
TG, mg/dl 150.4 (106.2–203.5) 15
ata are presented as mean  SD, % (n), or median (interquartile range). *Significantly different
EPIC  European Prospective Investigation of Cancer; HDL  high-density lipoprotein cholestero
G  triglyceride(s).r TC to HDL-C ratio. After adjustment for age, smoking,
aist circumference, physical activity, systolic blood pres-
ure (for sexes combined), and hormone replacement ther-
py use (for women), individuals with elevated lipid levels
ere at increased risk of CHD. Non–HDL-C was the
etter predictor for risk of future CHD with increasing
ategories of respective lipoproteins (HR: 2.39, 95% CI:
.91 to 2.99). We found no significant interaction between
ex and lipid categories.
In Table 3, the HRs for future CHD associated with a
-SD increase of the same lipid indexes are shown. Again,
ncreasing lipid levels were associated with an increased
HD risk. When sexes were analyzed together, the risk
ssociated with 1-SD increase of non–HDL-C (HR: 1.54
95% CI: 1.35 to 1.74, p  0.001]) was statistically higher
han the risk associated with 1-SD increase of either
DL-C (HR: 1.22 [95% CI: 1.17 to 1.27, p 0.001]), TG
HR: 1.14 [95% CI: 1.09 to 1.19, p  0.001]), or the TC
o HDL-C ratio (HR: 1.19 [95% CI: 1.14 to 1.24, p 
.001]). We also tested for interaction between sex and
ipids and found that there was a significant interaction
etween sex and LDL-C in predicting CHD risk (p 
.02). There was no other sex-lipid interaction for the other
ipids.
In order to investigate whether individuals with high
on-HDL levels, high TG levels, or with a high TC to
DL-C ratio were at increased risk irrespective of LDL-C
evels, we classified our study sample in 4 groups according
hoNot Develop CHDIC-Norfolk Who
nts Who Did Not Develop CHD
Women
th CHD Without CHD With CHD
,310 11,324 776
 8* 58 9 66 7*
9)* 11.2 (1,267) 14.0 (109)*
4)* 31.4 (3,557) 35.8 (278)*
7)* 57.4 (6,500) 50.1 (389)*
N/A 21.5 (2,439) 12.0 (93)*
1)* 16.4 (1,853) 9.1 (71)*
1)* 23.3 (2,644) 17.0 (132)*
5)* 32.5 (3,681) 29.8 (231)*
3)* 27.8 (3,146) 44.1 (342)*
 10* 81 10 86 11*
 19* 133 18 143 19*
 12* 80 11 84 12*
 41.3* 240.5 45.2 261.8 47.5*
 37.1* 153.3 41.7 172.2 43.6*
 12.4* 61.0 16.2 56.8 15.4*
 49.0* 179.5 47.1 205.0 48.3*
 1.59* 4.22 1.43 4.93 1.54*
5.0–221.2)* 115.0 (88.5–168.1) 150.4 (115.0–212.4)*
articipants without coronary heart disease (CHD) (p  0.05).lk Wo Didin EP
ticipa
Wi
1
64
5.2 (19
9.8 (78
5.0 (32
7.6 (23
1.5 (28
2.5 (29
8.4 (50
98
143
86
242.1
161.0
45.6
196.1
5.61
9.3 (11
from p
l; LDL  low-density lipoprotein cholesterol; N/A  not applicable; TC  total cholesterol;
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Lipids and CHD Risk December 29, 2009/January 5, 2010:35–41o LDL-C targets suggested by the National Cholesterol
ducation Program-Adult Treatment Panel III. Table 4
hows that, even for participants with LDL-C100 mg/dl,
ndividuals with high non–HDL-C levels, high TG levels,
r with a high TC to HDL-C ratio were at increased risk
or CHD.
Finally, Kaplan-Meier survival curves showing the event-
ree survival during follow-up were calculated for study
articipants classified on the basis of LDL-C and TG levels
Fig. 1A), LDL-C and non–HDL-C levels (Fig. 1B), and
DL-C levels and the TC to HDL-C ratio (Fig. 1C). This
gure shows that that LDL-C does not help to discriminate
hose who developed CHD from those who did not once
on–HDL-C is taken into consideration. On the other
and, LDL-C and TG levels as well as LDL-C and the TC
o HDL-C ratio appear to be independently associated with
isk of future CHD.
iscussion
e observed that among apparently healthy men and
omen in a cohort representative of a contemporary West-
Rs for Future Coronary Heart Disease According toDL-C, Non–HDL-C, and Triglycer d Levels an the TC to HDL-C RaTable 2 Rs for Futu e Coronary Heart Disease Acc rding toLDL-C, Non–HDL-C, and Triglyceride Levels and the TC
LDL-C, mg/dl <100 100–129.9
Total, person-yrs 16,924 52,205
HR 1.00 1.15 (0.90–1.46)
Men, person-yrs 6,751 22,389
HR 1.00 1.15 (0.86–1.55)
Women, person-yrs 10,174 29,844
HR 1.00 1.08 (0.71–1.65)
Non–HDL-C, mg/dl <130 130–159.9
Total, person-yrs 6,374 52,394
HR 1.00 1.43 (1.13–1.83)
Men, person-yrs 8,501 21,736
HR 1.00 1.59 (1.16–2.18)
Women, person-yrs 17,859 30,654
HR 1.00 1.15 (0.79–1.69)
TG, mg/dl <150 150–199.9
Total, person-yrs 137,039 48,985
HR 1.00 1.25 (1.12–1.39)
Men, person-yrs 49,243 23,952
HR 1.00 1.17 (1.02–1.35)
Women, person-yrs 87,786 25,016
HR 1.00 1.31 (1.10–1.56)
TC/HDL-C <4.00 4.00–4.99
Total, person-yrs 89,089 61,443
HR 1.00 1.36 (1.20–1.56)
Men, person-yrs 23,007 27,914
HR 1.00 1.32 (1.09–1.58)
Women, person-yrs 66,041 33,546
HR 1.00 1.40 (1.16–1.69)
alues are n or hazard ratio (HR) (95% confidence interval). HRs were obtained after adjustments
ormone replacement therapy use (women).
Abbreviations as in Table 1.rn population, non–HDL-C, TG, and the TC to HDL-C latio were more strongly associated with risk of future CHD
han was LDL-C. We also found that at any LDL-C level,
ndividuals with elevated non–HDL-C levels, elevated TG
evels, or with an increased TC to HDL-C ratio were still at
n increased risk of developing CHD.
A number of studies have investigated the relationships
etween LDL-C and non–HDL-C as well as TG levels to
he risk of CHD (13). In a case-control study sample of the
ealth Professionals Follow-up Study, the HR for future
HD (top quintile vs. bottom quintile) was 2.76 (95% CI:
.66 to 4.58) for non–HDL-C, 2.41 (95% CI: 1.43 to 4.07)
or TG, and 1.81 (95% CI: 1.12 to 2.93) for LDL-C levels,
uggesting that these other traditional lipid parameters in
HD risk prediction may be more strongly associated with
HD risk than LDL-C is. Our results are also in agreement
ith those of the Lipid Research Clinics Program Longi-
udinal Follow-up Study, which investigated the relation-
hips between several lipid parameters and the risk of
ardiovascular mortality over a 19-year follow-up in 2,406
en and 2,058 women (14). Compared with men with
on–HDL-C levels 160 mg/dl, men with non–HDL-C
L-C Ratio
130–159.9 >160 p Value
72,062 93,850
1.30 (1.03–1.64) 1.81 (1.45–2.27) 0.001
33,138 38,130
1.38 (1.04–1.82) 1.95 (1.49–2.56) 0.001
38,896 55,705
1.07 (0.72–1.61) 1.41 (0.95–2.09) 0.001
160–189.9 >190
64,262 92,023
1.60 (1.27–2.02) 2.39 (1.91–2.99) 0.001
29,782 40,375
1.82 (1.34–2.46) 2.65 (1.98–3.55) 0.001
34,451 51,650
1.19 (0.83–1.71) 1.81 (1.28–2.56) 0.001
200–249.9 >250
26,660 22,375
1.26 (1.10–1.43) 1.57 (1.38–1.79) 0.001
14,093 13,097
1.20 (1.02–1.41) 1.49 (1.27–1.74) 0.001
12,562 9,277
1.29 (1.03–1.61) 1.61 (1.29–2.01) 0.001
5.00–5.99 >6.00
42,140 42,354
1.66 (1.45–1.91) 2.14 (1.88–2.44) 0.001
22,833 26,632
1.74 (1.45–2.09) 2.15 (1.81–2.56) 0.001
19,311 15,722
1.46 (1.18–1.81) 2.02 (1.65–2.48) 0.001
e, sex (total), smoking, waist circumference, physical activity, systolic blood pressure (total), andtio
to HD
for agevels220 mg/dl had an HR for future CHD of 2.14 (95%
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December 29, 2009/January 5, 2010:35–41 Lipids and CHD RiskI: 2.50 to 3.04), and compared with men with LDL-C
evels 130 mg/dl, men with LDL-C levels 190 mg/dl
ad an HR for future CHD of 1.77 (95% CI: 1.22 to 2.59).
esults were similar among women. In men of the Fra-
ingham Offspring Study, 1-SD increment of LDL-C was
ssociated with an increased CHD risk (HR: 1.11 [95% CI:
.97 to 1.27]) and the HRs for future CHD were 1.22 (95%
I: 1.06 to 1.40) and 1.39 (95% CI: 1.22 to 1.58),
espectively, for non–HDL-C levels and the TC to HDL-C
atio (15). In women, the HRs for future CHD were 1.20
95% CI: 0.99 to 1.46), 1.28 (95% CI: 1.06 to 1.56), and
.39 (95% CI: 1.17 to 1.66), respectively, for 1-SD incre-
ent of LDL-C, non–HDL-C, and the TC to HDL-C
atio. The importance of the TC to HDL-C ratio as
pposed to other parameters of the lipoprotein-lipid profile
as also highlighted in the Québec Cardiovascular Study as
ell as in the Women’s Health Study (16). These prospec-
ive studies are consistent in showing that parameters of the
azard Ratios for Future CHDcco ing t 1-SD Increase in LDL-C,on–HDL-C, and TG Lev ls and the T to HDL-C Ratio
Table 3
Hazard Ratio for Future CHD
According to 1-SD Increase in LDL-C,
Non–HDL-C, and TG Levels and the TC to HDL-C Ratio
Hazard Ratio 95% CI p Value
LDL-C
Total 1.22 1.17–1.27 0.001
Men 1.27 1.20–1.35 0.001
Women 1.12 1.05–1.20 0.001
Non–HDL-C
Total 1.54 1.35–1.74 0.001
Men 1.46 1.25–1.71 0.001
Women 1.59 1.27–1.98 0.001
Triglycerides*
Total 1.14 1.09–1.19 0.001
Men 1.12 1.07–1.18 0.001
Women 1.15 1.07–1.24 0.001
TC/HDL-C
Total 1.19 1.14–1.24 0.001
Men 1.17 1.12–1.23 0.001
Women 1.23 1.13–1.35 0.001
azard ratios were obtained after adjustments for age, sex (total), smoking, waist circumference,
hysical activity, systolic blood pressure (total), and hormone replacement therapy use (women).
On log-transformed values.
CI  confidence interval; other abbreviations as in Table 1.
azard Ratios for Future CHD According to Non–HDL-C and TG Levehe TC to HDL-C Ratio in Participants Classified on the Basis of LDTable 4 Hazard Ratios for Future CHD Accordi g to Non–HDL-Cthe TC to HDL-C Ratio in Participants Classified on the
Non–HDL-C <130 mg/dl Non–HDL-C >130 mg/
LDL-C 100 mg/dl 1.00 1.84 (1.12–3.04)
Non–HDL-C <160 mg/dl Non–HDL-C >160 mg/
LDL-C 100–129.9 mg/dl 1.00 1.26 (0.97–1.64)
Non–HDL-C <190 mg/dl Non–HDL-C >190 mg/
LDL-C 130–159.9 mg/dl 1.00 1.38 (1.12–1.69)
Non–HDL-C <190 mg/dl Non–HDL-C >190 mg/
LDL-C 160 mg/dl 1.00 1.78 (1.40–2.28)azard ratios were obtained after adjustments for age, sex (total), smoking, waist circumference, physic
Abbreviations as in Table 1.ipoprotein-lipid profile may be more closely associated with
HD incidence than LDL-C. However, the current guide-
ines recommend LDL-C as the primary lipid target, and
herefore the main question remains if there is any increased
isk associated with other lipids even at low levels of
DL-C. In our study, non–HDL-C levels appeared to be
he most important risk factor beyond LDL-C. We believe
han an important strength of the present study resides in
he fact that we have quantified the risk associated with
hese lipid parameters in each category of LDL-C levels,
rom low (100 mg/dl) to high (160 mg/dl). To the best
f our knowledge, the present study is the first prospective,
opulation-based study to suggest that the risk associated
ith elevated non–HDL-C levels, TG levels, or with an
levated TC to HDL-C ratio is present in any given
DL-C category, and especially in participants with low
DL-C levels.
Our results also provide epidemiological evidence to
ecent post-hoc analyses of important lipid-lowering trials
hat have reported that independently from LDL-C levels,
ndividuals with either high non–HDL-C (8) or high TG
evels (17) could nevertheless be at increased CHD risk. In
he present analyses, we found that levels of LDL-C do not
rovide any additional risk for CHD to non–HDL-C
hereas at any given LDL-C level, non–HDL-C levels
ere associated with higher risk of CHD.
tudy limitations. It is important to point out that lipid
evels were determined in nonfasting samples that were not
btained after a standardized meal. This may have caused
andom misclassification of study participants and therefore
ould have reduced our ability to detect associations be-
ween either TG or non–HDL-C levels and CHD risk.
owever, recent studies have highlighted the usefulness of
onfasting TG levels in CHD risk prediction, possibly
ecause metabolic perturbations may be most pronounced
n the post-prandial state (18,19). Moreover, in daily life,
ndividuals are at the post-prandial state for the majority of
he time. However, despite being nonfasting, TG levels
f our study population were similar to those of participants
f the Framingham Heart Study and the National Health
nd Nutrition Examination Survey (20,21). Furthermore,
develsTG Levels and
is of LDL-C Levels
TG <150 mg/dl TG >150 mg/dl TC/HDL-C <5 TC/HDL-C >5
1.00 1.63 (1.02–2.59) 1.00 2.19 (1.22–3.93)
1.00 1.11 (0.88–1.39) 1.00 1.27 (0.97–1.67)
1.00 1.30 (1.09–1.54) 1.00 1.46 (1.22–1.74)
1.00 1.26 (1.11–1.43) 1.00 1.42 (1.23–1.62)ls anL-C Land
Bas
dl
dl
dl
dlal activity, systolic blood pressure (total), and hormone replacement therapy use (women).
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dvanced age at the time of enrollment, a factor that could
ntroduce a survival bias. Also, we have no access to reliable
nformation about the use of lipid-lowering drugs at base-
ine or during follow-up. This may have led to underesti-
ation of the measures of associations between any lipid
ariable and CHD risk and therefore, does not negate our
ndings. Finally, it is important to mention that we did not
nclude stroke as an end point. As a consequence, our results
ay not be extrapolated to the entire spectrum of cardio-
ascular disease, as they are limited to CHD. We believe
hat further studies are required to investigate whether
on–HDL-C, TG, or the TC to HDL-C ratio provide
dditional information to LDL-C with regard to stroke
isk.
onclusions
e observed that irrespective of LDL-C levels, participants
ith elevated non–HDL-C levels, elevated TG levels, or
ith an elevated TC to HDL-C ratio have a substantially
igher risk of developing CHD. We also found that
on–HDL-C levels not only account for the risk associated
ith LDL-C, but also provide more information about
HD risk associated with elevated lipid levels than LDL-C
evels alone. Based on these results, beyond LDL-C levels,
HD risk assessment algorithms as well as lipid targets for
ipid-lowering trials may also need to consider other easily
vailable parameters such as non–HDL-C.
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